BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MyoScience Inc. Lands $25 Million in Series E Financing


9/12/2013 6:19:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

myoscience Announces $25 Million Series E Financing Round

REDWOOD CITY, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- myoscience, inc., the makers of iovera degrees , is pleased to announce that it has closed on $25 million in Series E financing. The funds for the Series E financing came entirely from existing investors. The iovera degrees system uses Focused Cold Therapy(TM) to treat peripheral nerve conditions for both cosmetic and pain indications.

"We are all excited about the results of iovera degrees for cosmetic use in the European Union and Canada, and the growing potential of our product in the treatment of focal pain in the United States," says Clint Carnell, CEO of myoscience. "This financing demonstrates the high degree of commitment and confidence that the investors have in the company's potential."

"We are ready and willing to support the future growth of myoscience, expanding geography and indications to recognize the full potential of their platform technology," says Jan Pensaert of Valiance Asset Management Limited.

The Series E financing included the following existing investors:

Accuitive Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital, Saratoga Ventures, and Valiance Asset Management Limited.

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy(TM), the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581



CONTACT: Alexandra Mack, myoscience inc.

Tel: 00 1 650 421 0609

amack@myoscience.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES